Asthma mortality in Portugal: Impact of treatment with inhaled corticosteroids and leukotriene receptor antagonists

Treatments in Respiratory Medicine

Volumn 5, Issue 2, 2006, Pages 143-147

  De Melo, Magda Nunes ^a   Mendes, Zilda ^a   Martins, Paula ^a   Suissa, Samy ^b  

^a Centro de Estudos de Farmacoepidemiologia   (Portugal)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; ANTIASTHMATIC AGENT;

ARTICLE; ASTHMA; CONTROLLED STUDY; DRUG USE; HUMAN; MORTALITY; POPULATION RESEARCH; PORTUGAL; PRIORITY JOURNAL; INHALATIONAL DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ANTI-ASTHMATIC AGENTS; ASTHMA; HUMANS; LEUKOTRIENE ANTAGONISTS; PORTUGAL;

EID: 33744499185     PISSN: 11763450     EISSN: 11763450     Source Type: Journal    
DOI: 10.2165/00151829-200605020-00007     Document Type: Article

References (28)

1. Bucknall CE, Slack R, Godley CC, et al. Scottish confidential inquiry into asthma deaths (SCIAD), 1994-6. Thorax 1999 Nov; 54 (11): 978-84
2. Campbell MJ, Cogman GR, Holgate ST, et al. Age specific trends in asthma mortality in England and Wales, 1983-95: results of an observational study. BMJ 1997 May 17; 314 (7092): 1439-41
3. Goldman M, Rachmiel M, Gendler L, et al. Decrease in asthma mortality rate in Israel from 1991-1995: is it related to increased use of inhaled corticosteroids? J Allergy Clin Immunol 2000 Jan; 105 (1 Pt 1): 71-4
4. Picard E, Barmeir M, Schwartz S, et al. Rate and place of death from asthma among different ethnic groups in Israel: national trends 1980 to 1997. Chest 2002 Oct; 122 (4): 1222-7
5. Suissa S, Ernst P. Use of anti-inflammatory therapy and asthma mortality in Japan. Eur Respir J 2003 Jan; 21 (1): 101-4
6. Boulet LP, Becker A, Berube D, et al. Canadian asthma consensus report, 1999. Canadian Asthma Consensus Group. CMAJ 1999 Nov 30; 161 (11 Suppl.): S1-61
7. British Thoracic Society. Guidelines for asthma management. Thorax 1997; 52: S1-21
8. Makino SFK, Miyamoto T, Ohta K. Asthma prevention and management guidelines. Ministry of Health and Welfare, Japan. Int Arch Allergy Immunol 2000; 121 Suppl. 1: 1-77
9. Barnes PJ. Current issues for establishing inhaled corticosteroids as the antiinflammatory agents of choice in asthma. J Allergy Clin Immunol 1998 Apr; 101 (4 Pt 2): S427-33
10. Hargreave FE, Dolovich J, Newhouse MT. The assessment and treatment of asthma: a conference report. J Allergy Clin Immunol 1990 Jun; 85 (6): 1098-111
11. Global Initiative for Asthma. Pocket guide for asthma management and prevention. Bethesda (MD): NIH, 2003. Report No.: Updated from NHLBI/WHO Workshop Report: Global Strategy for Asthma Management and Prevention issued January 1995 and revised 2002. NIH Publication No. 02-3659
12. Suissa S, Ernst P, Kezouh A. Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. Thorax 2002 Oct; 57 (10): 880-4
13. Blais L, Suissa S, Boivin J, et al. First treatment with inhaled corticosteroids and the prevention of admissions to hospital for asthma. Thorax 1998; 53: 1025-9
14. Sin DD, Tu JV. Inhaled corticosteroid therapy reduces the risk of rehospitalization and all-cause mortality in elderly asthmatics. Eur Respir J 2001 Mar; 17 (3): 380-5
15. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 2002; 113: 59-65
16. Suissa S, Ernst P, Benayoun S, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000 Aug 3; 343 (5): 332-6
17. Kips JC, Pauwels RA. Low dose inhaled corticosteroids and the prevention of death from asthma. Thorax 2001 Sep; 56 Suppl. 2: ii74-8
18. Lanes SF, Garcia Rodriguez LA, Huerta C. Respiratory medications and risk of asthma death. Thorax 2002 Aug; 57 (8): 683-6
19. Lipworth BJ. Leukotriene-receptor antagonists. Lancet 1999 Jan 2; 353 (9146): 57-62
20. International Classification of Diseases 9th revision - clinical modification. Ann Arbor (MI): Commission on Professional and Hospital Activities, 1991
21. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for DDDs. 2nd ed. Oslo, Norway: WHO Collaborating Centre for Drug Statistics Methodology, 1993
22. WHO Collaborating Centre for Drug Statistics Methodology. Anatomic Therapeutic Chemical (ATC) classification index with Defined Daily Doses (DDDs). January 2001 ed. Oslo, Norway: WHO Collaborating Centre for Drug Statistics Methodology, 2001
23. Garrett J, Kolbe J, Richards G, et al. Major reduction in asthma morbidity and continued reduction in asthma mortality in New Zealand: what lessons have been learned? Thorax 1995 Mar; 50 (3): 303-11
24. Rothman KJ, Greenland S. Modern epidemiology. 2nd ed. Philadelphia (PA): Lippincott Williams & Wilkins, 1998
25. Nogueira PJ, Falcão JM. Causas de morte com alterações inesperadas em 1998. 1st ed. Lisboa: Instituto Nacional de Saúde Dr. Ricardo Jorge; Ministério da Saúde, 2001
26. Masoli M, Fabian D, Holt S, et al. Global burden of asthma. Allergy 2004; 59: 469-78
27. Jackevicius CA, Chapman KR. Prevalence of inhaled corticosteroid use among patients with chronic obstructive pulmonary disease: a survey. Ann Pharmacother 1997 Feb; 31 (2): 160-4
28. Monsanto A, Ascensão P. Bronquite crónica e asma. Luso: Reunião anual dos Médicos Sentinela, 1997